Metabolomic Approaches to Chronic Kidney Disease

Chronic kidney disease (CKD) represents a major global health challenge, driven by rising rates of diabetes, hypertension and an ageing population. Traditional clinical markers such as creatinine and albuminuria often detect renal impairment only after substantial damage has occurred. Metabolomic approaches offer a comprehensive analysis of small-molecule metabolites in biofluids and tissues, enabling early detection, mechanistic insight and identification of novel therapeutic targets. Advances in liquid chromatography–mass spectrometry, capillary electrophoresis–MS and nuclear magnetic resonance spectroscopy now allow high-throughput profiling of hundreds to thousands of metabolites. Comparative studies of plasma, urine and renal tissue across CKD stages have uncovered panels of uremic solutes, amino acid derivatives, lipid species and gut-derived compounds that correlate with estimated glomerular filtration rate, tubular dysfunction and inflammatory pathways. Longitudinal investigations demonstrate that specific metabolites—such as acylcarnitines and tryptophan catabolites—predict progression to end-stage kidney disease. Integrative analyses combining metabolomic and proteomic data are elucidating the pathways of fibrosis, oxidative stress and endothelial injury in CKD. The translation of non-targeted discovery into targeted assays has yielded robust reference ranges for novel markers like C-mannosyltryptophan, pseudouridine and N,N,N-trimethyl-L-alanyl-L-proline betaine, supporting their potential clinical application for risk stratification and personalised management. These advances underscore the interplay between host metabolism, diet and the gut microbiome in CKD pathogenesis and open avenues for precision therapeutics.

Research from Nature Portfolio

Recent studies have applied capillary electrophoresis and liquid chromatography mass spectrometry to profile over 200 plasma metabolites in prospective CKD cohorts, identifying 16 compounds whose elevated levels confer a two- to eightfold increased risk of progression to end-stage kidney disease. A bidirectional Mendelian randomisation analysis has clarified that reduced glomerular filtration drives accumulation of tryptophan pathway metabolites—such as kynurenine, C-glycosyltryptophan and 3-indoxyl sulfate—highlighting their role as biomarkers of declining renal function rather than causal agents. Further work has translated non-targeted discovery into quantitative assays, establishing plasma and urinary reference intervals and fractional excretion values for C-mannosyltryptophan and pseudouridine in individuals with and without CKD, thereby advancing their readiness for clinical implementation.

Metabolomic Approaches to Chronic Kidney Disease publication trend

The graph below shows the total number of articles in metabolomic approaches to chronic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: Systematic study of small-molecule metabolites in biological specimens to characterise biochemical status.

Biomarker: Measurable indicator of normal or pathological processes or responses to therapeutic intervention.

eGFR (estimated glomerular filtration rate): Calculated index of kidney filtering capacity commonly used to stage CKD.

Mass spectrometry (MS): Analytical technique measuring mass-to-charge ratios of ionised compounds for identification and quantification.

Nuclear magnetic resonance (NMR) spectroscopy: Non-destructive method for determining molecular structures and concentrations based on magnetic properties of atomic nuclei.

Uremic solutes: Waste metabolites that accumulate in the blood when kidney excretory function declines.

References

1. Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases. Metabolites (2019).
2. Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease. PLOS ONE (2014).
3. An Enlarged Profile of Uremic Solutes. PLOS ONE (2015).
4. Amino Acid Metabolites Associated with Chronic Kidney Disease: An Eight-Year Follow-Up Korean Epidemiology Study. Biomedicines (2020).
5. New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. International Journal of Molecular Sciences (2020).
6. Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling. Scientific Reports (2016).
7. The relationship between blood metabolites of the tryptophan pathway and kidney function: a bidirectional Mendelian randomization analysis. Scientific Reports (2020).
8. From Discovery to Translation: Characterization of C-Mannosyltryptophan and Pseudouridine as Markers of Kidney Function. Scientific Reports (2017).
9. Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function. Scientific Reports (2019).